MenaQ7 verified by the Non-GMO Project

Published: 7-Apr-2016
Ingredients Regulatory Dietary supplements Active Nutrition Food

MenaQ7 is the best documented, commercially available vitamin K2 as MK-7 with guaranteed actives and stability, clinical substantiation and international patents granted and pending

NattoPharma is proud to announce that its complete line of MenaQ7 vitamin K2 as MK-7 has received verification from the Non-GMO Project, a non-profit 501(c)3 organisation that offers North America’s only third party verification and labelling for non-GMO (genetically modified organism) food and products.

'MenaQ7 has always been non-GMO, yet obtaining Non-GMO Project verification helps reinforce our commitment to our partners, who seek to offer the safest, healthiest finished products available,' says Eric Anderson, Senior Vice President of global sales and marketing with NattoPharma.

'Consumers are actively seeking out non-GMO products, so having the Non-GMO Project verify our line in accordance with their standard provides our partners an added level of support they rightfully expect,' Anderson continues. 'Further, it perpetuates MenaQ7’s reputation as being the leading vitamin K2 as MK-7 brand.'

  • Companies:
  • NattoPharma
See more

You may also like

Ingredients

Gnosis by Lesaffre highlights vitamin K2 doctoral thesis

Read more
Wasilewski was under the supervision of Prof Leon Schurgers, a co-leader in the multidisciplinary research project together with Dr Hogne Vik, CMO at Gnosis by Lesaffre

Trending Articles

  1. The perfect pair: how vitamins K2 and D3 combine to support health and well-being Hydrogen and oxygen, Yin and Yang, Batman and Robin; the world is full of iconic duos that combine to become more than the sum of their parts. One relatively unknown yet equally powerful partnership is that of vitamins D3 and K2
  2. LifeinU BSCU1: embrace your health now and for the future New biotics solutions are flooding the market to capitalise on the ever-changing immunity seeking consumer. However, one probiotic solution, LifeinU® BSCU1 from Gnosis by Lesaffre, has not only shown proven efficacy for immune support, but exciting new evidence confirms its protective role for immunity and beyond
  3. Macalat earns NEXTY award for chocolate mushroom mycelium technology The organic brand has created a novel category in the chocolate industry: sweet dark chocolate
  4. Mibelle Biochemistry has strengthened its beauty-from-within portfolio PhytoCellTec Md Nu, a novel anti-aging solution, utilises the power of apple fruit cell culture extract to boost skin stem cell vitality and enhance skin density, elasticity, and firmness, offering a rejuvenated skin experience

Upcoming event

Vitafoods Europe

14–16 May 2024 | Exhibition | Palexpo, Geneva See all

You may also like

Ingredients

Gnosis by Lesaffre highlights vitamin K2 doctoral thesis

Wasilewski was under the supervision of Prof Leon Schurgers, a co-leader in the multidisciplinary research project together with Dr Hogne Vik, CMO at Gnosis by Lesaffre
Ingredients

Vitamin K2 pioneers merge, creating the most comprehensive K2 offer
Regulatory

NattoPharma secures patents in Canada and South Korea

The company has patented its process for creating vitamin K2 as MK-7
Regulatory

MenaQ7 K2 cardiovascular study registered in Greece

The multi-centre, placebo-controlled, randomised, open-label intervention clinical trial will be done with peritoneal dialysis (PD) patients
Ingredients

Gnosis by Lesaffre expands K2 business with acquisition

Gnosis’ vitaMK7 and NattoPharma’s MenaQ7 solutions have been on the market, formulated in nutraceutical and functional food products, for more than 10 years
Ingredients

Vitamin K2: The heart-health insurance policy

COVID-19 reshaped how we view health, which has shone a light on Vitamin K2 as an essential supportive -- and protective -- nutrient.
Cardiovascular

How MenaQ7 K2 Breaks the Calcification Curve

Calcification is a dangerous process that results from a vitamin K2 deficiency. When bodies do not have enough K2, calcium does not bind to the bone mineral matrix. Rather, it deposits in arteries and soft tissues where it increases cardiovascular risks.
Subscribe now